{"nctId":"NCT02264821","briefTitle":"Wound Infusion vs Spinal Morphine for Post-caesarean Analgesia","startDateStruct":{"date":"2012-02"},"conditions":["Post Caesarean Analgesia"],"count":192,"armGroups":[{"label":"ropivacaine infiltration","type":"EXPERIMENTAL","interventionNames":["Drug: ropivacaine infiltration"]},{"label":"rachi morphine","type":"EXPERIMENTAL","interventionNames":["Drug: intrathecal morphine"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"ropivacaine infiltration","otherNames":["Naropin","local anesthetic"]},{"name":"intrathecal morphine","otherNames":["spinal morphine"]},{"name":"placebo","otherNames":["Nacl 0,9 %, saline solution"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients aged 18 years and more, ASA 1 or ASA 2, pregnant with at least 34 weeks of gestational age, admitted for a planned caesarian with a Pfannenstiel incision and having signed the informed consent form.\n\nExclusion Criteria:\n\n* Refusal of the patient or contra-indication to locoregional anesthesia\n* Allergy to the products used\n* ASA 3\n* ASA 4\n* Sleep apnea syndrome and/or obesity (BMI \\> 35)\n* Size inferior to 155cm\n* existence of a language barrier","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Effective Analgesia","description":"T0 until first request of morphine PCAIV","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"351","spread":null},{"groupId":"OG001","value":"380","spread":null},{"groupId":"OG002","value":"247","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Morphine Side Effects: Nausea, Vomiting, Pruritus.","description":"Is there a decrease of the incidence of morphine side effects such as nausea, vomiting, pruritus?","paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"Morphine Consumption","description":"Morphine consumption with PCAIV","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"20.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":63},"commonTop":["Pruritus","Hypotension","Nausea and/or vomiting"]}}}